- Home
- PHAR vs CAC Comparison
PHAR vs CAC Comparison
Compare PHAR & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- CAC
- Stock Information
- Founded
- PHAR 1988
- CAC 1875
- Country
- PHAR Netherlands
- CAC United States
- Employees
- PHAR N/A
- CAC N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- CAC Major Banks
- Sector
- PHAR Health Care
- CAC Finance
- Exchange
- PHAR Nasdaq
- CAC Nasdaq
- Market Cap
- PHAR 951.7M
- CAC 688.3M
- IPO Year
- PHAR N/A
- CAC 1997
- Fundamental
- Price
- PHAR $14.60
- CAC $39.82
- Analyst Decision
- PHAR Strong Buy
- CAC Buy
- Analyst Count
- PHAR 3
- CAC 3
- Target Price
- PHAR $30.00
- CAC $48.00
- AVG Volume (30 Days)
- PHAR 12.7K
- CAC 56.5K
- Earning Date
- PHAR 10-23-2025
- CAC 10-28-2025
- Dividend Yield
- PHAR N/A
- CAC 4.22%
- EPS Growth
- PHAR N/A
- CAC 4.80
- EPS
- PHAR N/A
- CAC 3.11
- Revenue
- PHAR $339,836,000.00
- CAC $197,501,000.00
- Revenue This Year
- PHAR $16.63
- CAC $42.11
- Revenue Next Year
- PHAR $6.77
- CAC $5.51
- P/E Ratio
- PHAR N/A
- CAC $12.78
- Revenue Growth
- PHAR 22.44
- CAC 21.74
- 52 Week Low
- PHAR $7.31
- CAC $34.53
- 52 Week High
- PHAR $17.08
- CAC $50.07
- Technical
- Relative Strength Index (RSI)
- PHAR 56.71
- CAC 47.61
- Support Level
- PHAR $13.63
- CAC $39.82
- Resistance Level
- PHAR $15.27
- CAC $40.75
- Average True Range (ATR)
- PHAR 0.96
- CAC 0.84
- MACD
- PHAR -0.13
- CAC -0.08
- Stochastic Oscillator
- PHAR 51.83
- CAC 16.49
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.